Department of Molecular Medicine and Surgery, Center for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, Solna-17176, Stockholm, Sweden.
Adv Exp Med Biol. 2010;654:611-26. doi: 10.1007/978-90-481-3271-3_26.
Type 1 diabetes (T1D) is an autoimmune disease resulting from the destruction of pancreatic beta-cells. The main aim of treatment should be to prevent beta-cell destruction and preserve existing beta-cells in individuals with progressive autoimmunity. This can be achieved in several ways and in this chapter the authors have reviewed recent approaches that are currently being tested in animal models and human T1D patients under the following categories: i) antigen based therapy, ii) antibody-based therapy iii) other forms of therapy and iv) failed therapies.
1 型糖尿病(T1D)是一种自身免疫性疾病,由胰腺β细胞破坏引起。治疗的主要目的应该是预防β细胞破坏,并在有进行性自身免疫的个体中保留现有的β细胞。这可以通过多种方式实现,在本章中,作者根据以下类别回顾了目前正在动物模型和人类 T1D 患者中进行测试的最新方法:i)抗原治疗,ii)抗体治疗,iii)其他形式的治疗,iv)失败的治疗。